Key TakeawaysRoivant shares jumped 8% today after brepocitinib met the main goal and every key secondary goal in two Phase 3 trials in non-infectious uveitis. The results make uveitis a likely second ...

Lisraya, an oral tyrosine kinase 2/Janus kinase inhibitor, achieved its primary endpoint in two phase 3 clinical trials ...

Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key ...

An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease ...

Roivant Sciences (ROIV) added nearly 7% in the premarket on Wednesday after the company and its subsidiary, Priovant ...

Analysts are currently heralding Lisraya as a potential competitor for the standard of care title in NIU.

A narrative review identifies aqueous-humor extracellular-vesicle microRNAs as promising but unvalidated candidates for characterizing the local intraocular environment in HSV-1 anterior uveitis.

What Are Treatments for Uveitis? Uveitis is the inflammation of your uvea — the middle layer of your eye. It can happen for many reasons, but up to 70% of cases have unknown causes. It can affect a ...